|
|
|
|
Monday, June 15, 2020
Onconova Therapeutics Inc. (ONTX)
INSPIRE Study Patients’ Genomic Profile at the Baseline
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Genomic data is presented at EHA. Onconova’s main focus is the pivotal INSPIRE study, assessing rigosertib in the 2nd-line high-risk myelodysplastic syndrome (HR-MDS) patients. The company presented genomic data at the baseline from 190 patients enrolled in this study.
Future genomic data will be meaningful for the rigosertib clinical response. The baseline patient mutational profile showed that RAS pathway mutations were observed more commonly in patients that progressed on hypomethylating agents (HMA) therapy versus patients that failed HMA therapy. These results set the mutational profile for the patients prior to study treatment. The mutational analysis after the treatment will provide….
Click to get the full report.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.